TY - JOUR
T1 - A personalized physical activity program with activity trackers and a mobile phone app for patients with metastatic breast cancer
T2 - Protocol for a single-arm feasibility trial
AU - Delrieu, Lidia
AU - Pérol, Olivia
AU - Fervers, Béatrice
AU - Friedenreich, Christine
AU - Vallance, Jeff
AU - Febvey-Combes, Olivia
AU - Pérol, David
AU - Canada, Brice
AU - Roitmann, Eva
AU - Dufresne, Armelle
AU - Bachelot, Thomas
AU - Heudel, Pierre Etienne
AU - Trédan, Olivier
AU - Touillaud, Marina
AU - Pialoux, Vincent
N1 - Publisher Copyright:
© Lidia Delrieu, Olivia Pérol, Béatrice Fervers, Christine Friedenreich, Jeff Vallance, Olivia Febvey-Combes, David Pérol, Brice Canada, Eva Roitmann, Armelle Dufresne, Thomas Bachelot, Pierre-Etienne Heudel, Olivier Trédan, Marina Touillaud, Vincent Pialoux. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 30.08.2018. This is an open-access article distributed under the terms of the Creative Commons Attribution License.
PY - 2018/8
Y1 - 2018/8
N2 - Background: About 5% of breast cancer cases are metastatic at diagnosis, and 20%-30% of localized breast cancer cases become secondarily metastatic. Patients frequently report many detrimental symptoms related to metastasis and treatments. The physical, biological, psychological, and clinical benefits of physical activity during treatment in patients with localized breast cancer have been demonstrated; however, limited literature exists regarding physical activity and physical activity behavior change in patients with metastatic breast cancer. Objective: The primary objective of this study is to assess the feasibility of a 6-month physical activity intervention with activity trackers in patients with metastatic breast cancer (the Advanced stage Breast cancer and Lifestyle Exercise, ABLE Trial). Secondary objectives are to examine the effects of physical activity on physical, psychological, anthropometrics, clinical, and biological parameters. Methods: We plan to conduct a single-center, single-arm trial with 60 patients who are newly diagnosed with metastatic breast cancer. Patients will receive an unsupervised and personalized 6-month physical activity program that includes an activity tracker Nokia Go and is based on the physical activity recommendation. Patients will be encouraged to accumulate at least 150 minutes per week of moderate-to-vigorous intensity physical activity. Baseline and 6-month assessments will include anthropometric measures, functional tests (eg, 6-minute walk test and upper and lower limb strength), blood draws, patient-reported surveys (eg, quality of life and fatigue), and clinical markers of tumor progression (eg, Response Evaluation Criteria In Solid Tumors criteria). Results: Data collection occurred between October 2016 and January 2018, and the results are expected in August 2018. Conclusions: The ABLE Trial will be the first study to assess the feasibility and effectiveness of an unsupervised and personalized physical activity intervention performed under real-life conditions with activity trackers in patients with metastatic breast cancer.
AB - Background: About 5% of breast cancer cases are metastatic at diagnosis, and 20%-30% of localized breast cancer cases become secondarily metastatic. Patients frequently report many detrimental symptoms related to metastasis and treatments. The physical, biological, psychological, and clinical benefits of physical activity during treatment in patients with localized breast cancer have been demonstrated; however, limited literature exists regarding physical activity and physical activity behavior change in patients with metastatic breast cancer. Objective: The primary objective of this study is to assess the feasibility of a 6-month physical activity intervention with activity trackers in patients with metastatic breast cancer (the Advanced stage Breast cancer and Lifestyle Exercise, ABLE Trial). Secondary objectives are to examine the effects of physical activity on physical, psychological, anthropometrics, clinical, and biological parameters. Methods: We plan to conduct a single-center, single-arm trial with 60 patients who are newly diagnosed with metastatic breast cancer. Patients will receive an unsupervised and personalized 6-month physical activity program that includes an activity tracker Nokia Go and is based on the physical activity recommendation. Patients will be encouraged to accumulate at least 150 minutes per week of moderate-to-vigorous intensity physical activity. Baseline and 6-month assessments will include anthropometric measures, functional tests (eg, 6-minute walk test and upper and lower limb strength), blood draws, patient-reported surveys (eg, quality of life and fatigue), and clinical markers of tumor progression (eg, Response Evaluation Criteria In Solid Tumors criteria). Results: Data collection occurred between October 2016 and January 2018, and the results are expected in August 2018. Conclusions: The ABLE Trial will be the first study to assess the feasibility and effectiveness of an unsupervised and personalized physical activity intervention performed under real-life conditions with activity trackers in patients with metastatic breast cancer.
KW - Activity trackers
KW - Feasibility
KW - Metastatic breast cancer
KW - Oxidative stress
KW - Physical activity
UR - http://www.scopus.com/inward/record.url?scp=85096028695&partnerID=8YFLogxK
U2 - 10.2196/10487
DO - 10.2196/10487
M3 - Journal Article
AN - SCOPUS:85096028695
VL - 20
JO - JMIR Research Protocols
JF - JMIR Research Protocols
IS - 8
M1 - e10487
ER -